Generation of the acute phencyclidine rat model for proteomic studies of schizophrenia

Dan Ma, Paul C. Guest*

*Corresponding author for this work

Research output: Chapter in Book/Published conference outputChapter


Administration of the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist phencyclidine (PCP) to rodents has been used as the gold standard preclinical model for schizophrenia. PCP treatment induces hyperlocomotion and stereotypic behaviour, which resemble the positive symptoms of schizophrenia. In addition, proteomic studies have identified changes in proteins associated with energy metabolism and neurotransmission which are typical hallmarks of the disease. This chapter presents a protocol for the generation of this model, behavioural assessment and preparation of key bio-samples to provide the raw materials for proteomic analyses.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
EditorsP. Guest
Number of pages5
ISBN (Electronic)978-3-319-52479-5
ISBN (Print)978-3-319-52478-8
Publication statusPublished - 29 Mar 2017

Publication series

NameAdvances in Experimental Medicine and Biology
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019


  • Behaviour
  • Brain tissue
  • PCP
  • Proteomics
  • Rat model
  • Schizophrenia
  • Serum


Dive into the research topics of 'Generation of the acute phencyclidine rat model for proteomic studies of schizophrenia'. Together they form a unique fingerprint.

Cite this